Would you recommend TTFields in a GBM patient with a poor PS receiving hypofractionated chemoradiation?

Given the use burden (scalp shaving, array changes, etc.) I would anticipate patient/caregiver compliance to be quite low in this population. Given the modest survival benefit in good performers (~3 months), I think the burden would outweigh the benefit in this subset. If more substantial survival gains are observed from EF-41/KEYNOTE D58 with concurrent pembrolizumab, I would consider extending beyond ECOG 0-1 in the future; however, Optune adherence can be challenging even for baseline robust patients.